Cinderella's tale of Novavax heads towards an alternate ending #vaccine #Novavax
Vaccines may not be viable, and worse for NVAX stock, they are not that important
Novavax (NASDAQ: NVAX) that was one of the 2020 Cinderella stories has fallen sharply from its August highs. Most likely, the facts of an accelerated new coronavirus vaccine program known as Operation Warp Speed are coming to bite the shares of NVAX and its competitors like Moderna (NASDAQ: MRNA).
In the best of circumstances, vaccines take years to develop and distribute. Now, they have to do it by January 2021 and if President Trump is on his way, before November 3.
So, the news that Novavax has reached an agreement in principle with the Canadian government to supply our northern neighbour with 76 million doses was a much-needed relief for the recently besieged stakeholders. According to management, Novavax expects to close the agreement "early in the second quarter of 2021". The deal is conditional on the approval of the Canadian Ministry of Health.
Additionally, Novavax can ride this momentum higher thanks to the basic nature of the pollen filter. As you know, multiple pharmaceutical and biotech companies are part of this unprecedented effort. Not surprisingly, then, there are multiple ways to solve the mystery of the new Coronavirus.
Novavax is working with the subunit vaccine design, which could be a great step up. Primarily, only monocyte vaccines contain the antigens necessary to make the platform work; Hence, they do not have other molecules that make up the target microbes. This makes subunit vaccines suitable for those with weakened immune systems, giving NVAX stocks an edge over competitors.
As you know, health officials have consistently warned that people with underlying conditions are at a higher risk.
No comments:
Post a Comment